Fatigue News and Research

RSS

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a "natural" dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

2 Jun 2012

Longer looks: The cost of dying; Insuring fertility

During those four days Terence had his blood drawn - eight times. Urine collected at least twice. There was a CT scan of his chest and an MRI of his brain. A physical therapist dropped by several times. A nutritionist talked about cancer fatigue, decompensation, and calorie needs. Over the stay, at least 29 professionals - nurses, physical therapists, a nutritionist, and nine M.D.s - attended to his needs.

1 Jun 2012

Experimental drug shows promise for elderly chronic leukemia patients

The experimental drug ibrutinib is highly active and well tolerated in elderly, treatment-naive patients with chronic lymphocytic leukemia, US researchers report.

30 May 2012

Dehydration: how much should we drink per day?

As the northern hemisphere approaches the summer months, many of us begin to think about drinking more to prevent dehydration. But exactly how much should we be drinking a day? Does the amount vary depending on what we are drinking? And what happens if we don’t drink enough fluid?

30 May 2012

IACFS/ME releases new guidelines for chronic fatigue syndrome

The International Association for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (IACFS/ME), the largest group of physicians and researchers dedicated to chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), has released updated care guidelines directed at primary care physicians and other health care providers.

30 May 2012

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa (perampanel) as an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

29 May 2012

New diagnostic approach for Lyme disease

George Mason University researchers can find out if a tick bite means Lyme disease well before the bite victim begins to show symptoms.

25 May 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

Nordic walking enables heart failure patients to exercise more intensely

Nordic walking enables heart failure patients to exercise more intensely than walking without poles.

21 May 2012

Positive results from CardioKinetix Parachute system study on heart failure

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced two-year clinical results for the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device, a Percutaneous Ventricular Restoration (PVR) therapy for patients with ischemic heart failure.

19 May 2012

BHI expresses concern over use of long-range acoustic devices

In preparation for the thousands of anti-war activists expected to protest outside the NATO summit in Chicago this week, the city has reportedly ordered $1 million worth of riot-control equipment including a 'sound cannon' that can be used to emit pain-inducing sound waves of up to 150 decibels.

19 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Study demonstrates impact of epilepsy on child and parent sleep patterns

Researchers from Massachusetts General Hospital for Children in Boston have determined that pediatric epilepsy significantly impacts sleep patterns for the child and parents. According to the study available in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy (ILAE), sharing a room or co-sleeping with their child with epilepsy decreases the sleep quality and prevents restful sleep for parents.

18 May 2012

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

Arthritis rates set to soar

According to new estimates the number of people with arthritis is set to soar with predictions that 1,500,000 Scots will be living with the condition by 2030.

10 May 2012

Brief empathy training program improves resident physicians interactions with patients

Resident physicians' participation in a brief training program designed to increase empathy with their patients produced significant improvement in how patients perceived their interactions with the residents.

8 May 2012

New analysis on why some soldiers never seek PTSD care

U.S. Army researcher Maj. Gary H. Wynn, M.D., shared new analysis on why some Soldiers suffering from combat-related post-traumatic stress disorder (PTSD) never seek care or drop out of treatment early during a presentation today at the American Psychiatric Association's annual meeting. His presentation, "Epidemiology of Combat-Related PTSD in U.S. Service Members: Lessons Learned," also described the approaches the Army is using to address this issue and improve overall patient outcomes.

8 May 2012